Literature DB >> 21086019

The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL.

Francesco Carinci1, Lorenzo Monasta, Corrado Rubini, Daniela Stramazzotti, Annalisa Palmieri, Elisabetta Melloni, Alex Knowles, Luca Ronfani, Giorgio Zauli, Paola Secchiero.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21086019     DOI： 10.1007/s10637-010-9586-0

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  28 in total

1.  Squamous cell carcinoma of the oral tongue in the pediatric age group: a matched-pair analysis of survival.

Authors:  Luc G T Morris; Snehal G Patel; Jatin P Shah; Ian Ganly
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2010-07

2.  Squamous cell cancer of the head and neck with distant metastasis at presentation.

Authors:  David I Kuperman; Vorachart Auethavekiat; Douglas R Adkins; Brian Nussenbaum; Sharon Collins; Chaiyaporn Boonchalermvichian; Kathryn Trinkaus; Ling Chen; Daniel Morgensztern
Journal:  Head Neck       Date:  2010-09-24       Impact factor: 3.147

3.  Prognostic value of the sixth edition of the UICC's TNM classification and stage grouping for oral cancer.

Authors:  Matthias Kreppel; Hans Theodor Eich; Alexander Kübler; Joachim E Zöller; Martin Scheer
Journal:  J Surg Oncol       Date:  2010-10-01       Impact factor: 3.454

4.  Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.

Authors:  Shohei Koyama; Naoto Koike; Shinya Adachi
Journal:  J Cancer Res Clin Oncol       Date:  2001-12-12       Impact factor: 4.553

5.  A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions.

Authors:  M Giovarelli; P Musiani; G Garotta; R Ebner; E Di Carlo; Y Kim; P Cappello; L Rigamonti; P Bernabei; F Novelli; A Modesti; A Coletti; A K Ferrie; P L Lollini; S Ruben; T Salcedo; G Forni
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

Review 6.  Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L.

Authors:  Roberta Di Pietro; Giorgio Zauli
Journal:  J Cell Physiol       Date:  2004-12       Impact factor: 6.384

7.  Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression.

Authors:  Cheng-Chang Yeh; Yi-Ting Deng; De-Yuan Sha; Michael Hsiao; Mark Yen-Ping Kuo
Journal:  Mol Cancer Ther       Date:  2009-09-08       Impact factor: 6.261

8.  TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors.

Authors:  Giorgio Zauli; Erika Rimondi; Susanna Stea; Fabio Baruffaldi; Marco Stebel; Carlotta Zerbinati; Federica Corallini; Paola Secchiero
Journal:  J Cell Physiol       Date:  2008-01       Impact factor: 6.384

Review 9.  Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis.

Authors:  Paola Secchiero; Giorgio Zauli
Journal:  Curr Opin Hematol       Date:  2008-01       Impact factor: 3.284

10.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression.

Authors:  K Song; Y Chen; R Göke; A Wilmen; C Seidel; A Göke; B Hilliard; Y Chen
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307
View more
  1 in total

1.  The prognostic role of NK cells and their ligands in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.

Authors:  Sangeeta K Bisheshar; Emma J De Ruiter; Lot A Devriese; Stefan M Willems
Journal:  Oncoimmunology       Date:  2020-04-23       Impact factor: 8.110
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.